Amylyx Pharmaceuticals, Inc. AMLX
30.21 USD +0.71 (+2.41%)
At closeNov 10, 2026, 4:01 AM EST
30.10 -0.11 -0.37%
Pre-market · Nov 10, 4:01 AM ET
28.76 Day range 30.32
10.83 52-week range 41.14
- YTD
- +150.08%
- 1 year
- +145.41%
News
defenseworld.net Amylyx Pharmaceuticals Q3 Earnings Call Highlights Amylyx Pharmaceuticals (NASDAQ: AMLX) plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027…
seekingalpha.com Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical…
marketbeat.com Amylyx Pharmaceuticals Q3 Earnings Call Highlights Amylyx Pharmaceuticals NASDAQ: AMLX plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027…
benzinga.com Amylyx Pharma Q3 EPS $(0.38), Inline Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.38) per share which met the analyst consensus estimate. This is a 2.7 percent decrease over losses of $(0.37) per share from the same…
businesswire.com Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.
businesswire.com Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.
businesswire.com Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences.
benzinga.com Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39 Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.